The DOI matches its Crossref record.
XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recent translational data have identified XPO1 as a critical target of resistance to eprenetapopt + AZA.
“recent translational data have identified XPO1 as a critical target of resistance to eprenetapopt + AZA”
From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [49]
Citations
Cited by
Sorted by citations
Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere · doi:10.1002/hem3.70164 · Cited by 26
Self-citation
Metadata
- Authors
- Kruer, T. L., Quintana, A., Ferrall-Fairbanks, M., Zhang, L., Newman, H., McLemore, A. F., Yang, Q., Bencrentsil, N., Komrokji, R. S., Chaudhry, S., Totiger, T. M., Figueroa, M. K. E., Taylor, J., Sallman, D. A., & Padron, E.
- Affiliations
- Moffitt Cancer Center (US)
- 3J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL
- University of Miami (US)
- 8H. Lee Moffitt Cancer Research Institute, Department of Malignant Hematology, Tampa, FL
- Sylvester Comprehensive Cancer Center (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2022-11-15
- Volume
- 140
- Issue
- Supplement 1
- Pages
- 99-100
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4310162493
- Cited by
- 8
- References
- 0
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 2
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- CRM1, azacitidine, drug resistance, TP53 mutation, myeloid neoplasms, nuclear transport
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
